Nuria Cañete

Nuria Cañete

Auto-generated profile, based on publicly available information

Nuria Cañete

Liver Section, Gastroenterology Department, Hospital del Mar, Universitat Autònoma de Barcelona, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2018 in Hepatology
Verified
Journal Article
Closed access
PDF file
VHVirginia Hernández-Gea
Virginia Hernández-Gea
BPBogdan Procopet
Bogdan Procopet
ÁGÁlvaro Giráldez
Álvaro Giráldez
LALucio Amitrano
Lucio Amitrano
CVCandid Villanueva
Candid Villanueva
FCfor the International Variceal Bleeding Observational Study Group and Baveno Cooperation
for the International Variceal Bleeding Observational Study Group and Baveno Cooperation

1 July 2010 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
SMSilvia Montoliu
Silvia Montoliu
BBBelén Ballesté
Belén Ballesté
RPRamon Planas
Ramon Planas
MÁMarco Antonio Álvarez-González
Marco Antonio Álvarez-González
MRMònica Rivera
Mònica Rivera
RSRicard Solà
Ricard Solà

31 July 2013 in Hepatology
Verified
Journal Article
Open access
PDF file
CRCristina Ripoll
Cristina Ripoll
JGJoan Genescà
Joan Genescà
IAIsis K. Araujo
Isis K. Araujo
IGIsabel Graupera
Isabel Graupera
SASalvador Augustin
Salvador Augustin
JBJaime Bosch
Jaime Bosch
Outcome of variceal bleeding (VB) in patients with hepatocellular carcinoma (HCC) is unknown. We compared outcomes after VB in patients with and without HCC. All patients with HCC and esophageal VB admitted between 2007 and 2010 were included. Follow‐up was prolonged until death, transplantation, or June 2011. For each patient with HCC, a patient without HCC matched by age and Child‐Pugh class was selected. A total of 292 patients were included, 146 with HCC (Barcelona Classification of Liver Cancer class 0‐3 patients, A [in 25], B [in 29], C [in 45], and D [in 41]) and 146 without HCC. No differences were observed regarding previous use of prophylaxis, clinical presentation, endoscopic findings, and initial endoscopic treatment. Five‐day failure was similar (25% in HCC versus 18% in non‐HCC; P = 0.257). HCC patients had greater 6‐week rebleeding rate (16 versus 7%, respectively; P = 0.025) and 6‐week mortality (30% versus 15%; P = 0.003). Fewer patients with HCC received secondary prophylaxis after bleeding (77% versus 89%; P = 0.009), and standard combination therapy was used less frequently (58% versus 70%; P = 0.079). Secondary prophylaxis failure was more frequent (50% versus 31%; P = 0.001) and survival significantly shorter in patients with HCC (median survival: 5 months versus greater than 38 months in patients without HCC; P < 0.001). Lack of prophylaxis increased rebleeding and mortality. On multivariate analysis Child‐Pugh score, presence of HCC, portal vein thrombosis, and lack of secondary prophylaxis were predictors of death. Conclusions: Patients with HCC and VB have worse prognosis than patients with VB without HCC. Secondary prophylaxis offers survival benefit in HCC patients. (Hepatology 2013; 58:2079–2088)

7 March 2022 in Liver International
Verified
Journal Article
Open access
CJCESAR JIMENEZ
CESAR JIMENEZ
MVMeritxell Ventura-Cots
Meritxell Ventura-Cots
MSMargarita Sala
Margarita Sala
MCMargalida Calafat
Margalida Calafat
MGMontserrat Garcia‐Retortillo
Montserrat Garcia‐Retortillo
VVVíctor Vargas
Víctor Vargas
Background & Aims: Alcoholic hepatitis (AH) is associated with a high incidence of infection and mortality. Rifaximin reduces bacterial overgrowth and translocation. We aimed to study whether the administration of rifaximin as an adjuvant treatment to corticosteroids decreases the number of bacterial infections at 90 days in patients with severe AH compared to a control cohort.Methods: This was a multicentre, open, comparative pilot study of the addition of rifaximin (1200 mg/day/90 days) to the standard treatment for severe AH. The results were compared with a carefully matched historical cohort of patients treated with standard therapy and matching by age and model of end‐stage liver disease (MELD). We evaluated bacterial infections, liver‐related complications, mortality and liver function tests after 90 days.Results: Twenty‐one and 42 patients were included in the rifaximin and control groups respectively. No significant baseline differences were found between groups. The mean number of infections per patient was 0.29 and 0.62 in the rifaximin and control groups, respectively (p = .049), with a lower incidence of acute‐on‐chronic liver failure (ACLF) linked to infections within the treatment group. Liver‐related complications were lower within the rifaximin group (0.43 vs. 1.26 complications/patient respectively) (p = .01). Mortality was lower in the treated versus the control groups (14.2% vs. 30.9, p = .15) without significant differences. No serious adverse events were associated with rifaximin treatment.Conclusions: Rifaximin is safe in severe AH with a significant reduction in clinical complications. A lower number of infections and a trend towards a lower ACLF and mortality favours its use in these patients.

24 April 2017 in Liver Transplantation
Verified
Journal Article
Closed access
ESElsa Solà
Elsa Solà
SCSantiago Sanchez Cabús
Santiago Sanchez Cabús
EREzequiel Rodriguez
Ezequiel Rodriguez
CEChiara Elia
Chiara Elia
RCRaquel Cela
Raquel Cela
PGPere Ginès
Pere Ginès

26 September 2017 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
MPMarc Puigvehí
Marc Puigvehí
TBTeresa Broquetas
Teresa Broquetas
SCSusanna Coll
Susanna Coll
MGMontserrat Garcia‐Retortillo
Montserrat Garcia‐Retortillo
NCNuria Cañete
Nuria Cañete
JCJosé A. Carrión
José A. Carrión